Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

Oncotarget

Volumn 6, Issue 39, 2015, Pages 42008-42018

  Gray, Elin S ^a   Rizos, Helen ^b,g   Reid, Anna L ^a   Boyd, Suzanah C ^b,g   Pereira, Michelle R ^a   Lo, Johnny ^a   Tembe, Varsha ^c   Freeman, James ^a   Lee, Jenny H J ^c,d   Scolyer, Richard A ^e,g   Siew, Kelvin ^h   Lomma, Chris ^h   Cooper, Adam ^d   Khattak, Muhammad A ^i,j   Meniawy, Tarek M ^h,j   Long, Georgina V ^f,g   Carlino, Matteo S ^d,g   Millward, Michael ^h,j   Ziman, Melanie ^a,k  

^a EDITH COWAN UNIVERSITY   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g MELANOMA INSTITUTE AUSTRALIA   (Australia)

^h SIR CHARLES GAIRDNER HOSPITAL   (Australia)

ⁱ FIONA STANLEY HOSPITAL   (Australia)

^j UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^k UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

more..

Author keywords

Acquired resistance; CtDNA; Immunotherapy; MAPK inhibition; Melanoma

Indexed keywords

B RAF KINASE; CIRCULATING TUMOR DNA; DABRAFENIB; DNA; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

ADVANCED CANCER; ARTICLE; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE MUTATION; HUMAN; MALE; METASTATIC MELANOMA; MONOTHERAPY; NRAS GENE; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; ADULT; AGED; BLOOD; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; MELANOMA; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; OUTCOME ASSESSMENT; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM METASTASIS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; YOUNG ADULT;

EID: 84951757209     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5788     Document Type: Article

References (36)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417:949-954.
2. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, et al. A landscape of driver mutations in melanoma. Cell. 2012; 150:251-263.
3. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D and Halaban R. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med. 2010; 8:67.
4. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotypedriven therapeutic trials. PLoS One. 2012; 7:e35309.
5. Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF and Long GV. BRAF inhibitor activity in V600R metastatic melanoma. European journal of cancer. 2013; 49:1073-1079.
6. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA and Long GV. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clinical cancer research. 2012; 18:3242-3249.
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011; 364:2507-2516.
8. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Jr., Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380:358-365.
9. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandala M, Millward M, Arance A, Bondarenko I, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. The New England journal of medicine. 2014; 371:1877-1888.
10. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. The New England journal of medicine. 2015; 372:30-39.
11. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014; 4:80-93.
12. Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, Howle J, Saw R, Thompson JF, Kefford RF, Scolyer RA and Long GV. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical cancer research. 2014; 20:1965-1977.
13. Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, Howle J, Hayward NK, Johansson P, Scolyer RA, Kefford RF and Rizos H. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature communications. 2014; 5:5694.
14. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England journal of medicine. 2013; 369:134-144.
15. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010; 363:711-723.
16. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, et al. Nivolumab in previously untreated melanoma without BRAF mutation. The New England journal of medicine. 2015; 372:320-330.
17. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014; 384:1109-1117.
18. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R and Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical cancer research. 2009; 15:7412-7420.
19. Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH and Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clinical cancer research. 2013; 19:3936-3943.
20. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med. 2014; 6:224ra224.
21. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. The New England journal of medicine. 2013; 368:1199-1209.
22. Diaz LA, Jr., Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS and Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486:537-540.
23. Heitzer E, Ulz P and Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015; 61:112-123.
24. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, Bentley D, Chin TM, Brenton JD, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013; 497:108-112.
25. Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob JJ, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long GV, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. Journal of clinical oncology. 2013; 31:3205-3211.
26. Sanmamed MF, Fernandez-Landazuri S, Rodriguez C, Zarate R, Lozano MD, Zubiri L, Perez-Gracia JL, Martin-Algarra S and Gonzalez A. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem. 2015; 61:297-304.
27. Lipson EJ, Velculescu VE, Pritchard TS, Sausen M, Pardoll DM, Topalian SL and Diaz LA, Jr. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer. 2014; 2:42.
28. Tsao SC, Weiss J, Hudson C, Christophi C, Cebon J, Behren A and Dobrovic A. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Scientific reports. 2015; 5:11198.
29. Hodi FS, Ribas A, Daud A, Hamid O, Robert C and Kefford R. (2014). Evaluation of Immune-Related Response Criteria (irRC) in Patients With Advanced Melanoma Treated With the Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475). 2014 ASCO Annual Meeting. Chicago, US.
30. Long GV, Atkinson V, Ascierto P and Brady B. (2014). Nivolumab Improved Survival vs Dacarbazine in Patients with Untreated Advanced Melanoma. 2014 ASCO Annual Meeting. Chicago, USA.
31. Xue X, Teare MD, Holen I, Zhu YM and Woll PJ. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clin Chim Acta. 2009; 404:100-104.
32. Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, Lax S, Waldispuehl-Geigl J, Mauermann O, Mohan S, Pristauz G, Lackner C, Hofler G, Eisner F, Petru E, Sill H, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer. 2013; 133:346-356.
33. Mohan S, Heitzer E, Ulz P, Lafer I, Lax S, Auer M, Pichler M, Gerger A, Eisner F, Hoefler G, Bauernhofer T, Geigl JB and Speicher MR. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by wholegenome plasma DNA sequencing. PLoS Genet. 2014; 10:e1004271.
34. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM and Janne PA. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clinical cancer research. 2014; 20:1698-1705.
35. Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, Rizos H, Lo RS, Kefford RF, Scolyer RA and Long GV. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Molecular cancer therapeutics. 2012; 11:2704-2708.
36. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer. 2009; 45:228-247.